A series of updates on
Bio-Rad Laboratories indicates a mixed bag of developments. The company has received a group consensus rating of
'Hold' from various brokerages. Major investment firms such as
Gotham Asset Management,
Hound Partners LLC, and
Moore Capital Management have substantially increased their stake in the company. However,
Vanguard has disaggregated its holdings, showing zero shares.
Bio-Rad's Q4 earnings had missed estimates and the revenues did surpass, which resulted in stock price decline. The company returned to profitability with
Diagnostics Rebound, hinting at possible sustained recovery. There's an interesting fissure of underwhelming core growth and a shift in recurring revenue. Although being marked with a bearish trend due to forming a death cross, the company witnessed a soft rebound. Q4 adjusted earnings felt a fall while revenue seemed to rise, leading to a drop in share price after trading hours. Despite margin goals being met, the stock slid due to scrutiny amid NIH budget cuts and modest growth outlook.
Earnings Flash resolution reported a Q4 revenue of $693.2M against the FactSet estimate of $688.8M. Nevertheless, the stock remains undervalued according to some analysts.
Bio-Rad Laboratories Stocks News Analytics from Wed, 02 Dec 2020 21:42:53 GMT to Sat, 28 Mar 2026 17:00:01 GMT -
Rating 5
- Innovation 2
- Information 6
- Rumor -2
